Peptides and Tissue Healing
A straightforward look at what peptides are, what the current evidence shows, and what patients should understand before considering them.
This article is for educational purposes only and does not constitute medical advice or an endorsement of any compound. Always consult your physician before starting any new treatment or supplement.
I get asked about this constantly
Peptides are one of the most common topics that comes up in my clinic — from athletes recovering from ACL reconstruction, to weekend warriors dealing with tendon pain, to patients preparing for surgery who want to do everything possible to optimize their recovery.
The questions are usually some version of: Do peptides work? Should I take BPC-157? My trainer recommended TB-500 — is it safe? Can peptides help me heal faster?
This post is a look at the information and what we actually know.
What are peptides?
Peptides are short chains of amino acids — the building blocks of proteins. They occur naturally in the body and serve a wide range of biological functions, including signaling between cells, regulating inflammation, and stimulating tissue repair.
The peptides that patients typically ask about — BPC-157, TB-500 (thymosin beta-4), CJC-1295, ipamorelin, and others — are synthetic versions of naturally occurring or modified peptide sequences, usually administered by injection.
The theoretical appeal is straightforward: if certain peptides play a role in tissue healing and regeneration, perhaps administering them externally could accelerate recovery from injury or surgery.
To put peptides in context
Insulin is a peptide. So is glucagon. So are growth hormone and oxytocin. These are among the most well-studied, tightly regulated, and carefully dosed compounds in all of medicine — used only under physician supervision, with decades of human trial data behind them, and with clearly defined indications, dosing protocols, and known side effect profiles.
This is what it looks like when a peptide has cleared the bar for clinical use. The compounds currently being discussed in athletic and recovery communities have not cleared that bar. That is not a minor distinction.
What the science actually shows
Here is where I have to be direct with patients: the evidence base for most therapeutic peptides is very limited.
The majority of available research consists of animal studies — primarily rodent models. BPC-157, for example, has shown promising results in rat models of tendon, muscle, and ligament healing. TB-500 has shown effects on cell migration and angiogenesis in laboratory settings.
These findings are genuinely interesting from a scientific standpoint. But animal data does not reliably translate to human outcomes. Many compounds that show dramatic effects in rodent models fail to demonstrate meaningful benefit — or prove unsafe — when tested in humans.
The bottom line on evidence: As of 2025, there are no large-scale, peer-reviewed, randomized controlled trials in humans demonstrating that any of the commonly discussed therapeutic peptides reliably accelerate tissue healing, reduce re-injury rates, or improve surgical outcomes. The evidence base that exists is largely preclinical.
The regulatory history: Why this topic is confusing right now
Part of the reason peptides are so prominent in the conversation right now is a specific regulatory history that patients deserve to understand.
For several years prior to 2023, certain peptides including BPC-157 and TB-500 were available through compounding pharmacies in the United States — meaning licensed pharmacies that prepare custom medications for patients. They were not FDA-approved drugs, but they existed in a legal grey area under compounding pharmacy regulations that allowed them to be prescribed and dispensed.
In 2023, the FDA reclassified 19 of these peptides — moving them from a list of compounds that could be compounded to a category of substances that could not. Overnight, compounding pharmacies were notified they could no longer prepare these compounds. The FDA's stated rationale was insufficient safety data to support their continued availability outside of formal drug approval.
This decision was controversial. Proponents argued that no significant adverse events had been documented at scale and that the compounds were being removed not because of harm but because of a lack of formal clinical trials — a bar that no one had funded them to clear, in part because unpatentable compounds offer no commercial incentive for the expensive FDA approval process.
As of 2025, the FDA has signaled it is reviewing several of these compounds — including BPC-157 — for potential reclassification back to compoundable status. That process is ongoing.
What this means practically: patients purchasing peptides from websites selling "research use only" compounds are operating entirely outside any regulatory framework. There is no quality control, no verified dosing, and no assurance of what is actually in the product. This is separate from the question of whether the compounds work — it is a straightforward safety concern regardless of the biology.
Regulatory status
This is equally important to understand. Most therapeutic peptides currently discussed in athletic and recovery communities are:
Not FDA-approved for the indications they are being used for
Not regulated as pharmaceuticals — meaning purity, concentration, and safety are not independently verified
Banned by WADA (the World Anti-Doping Agency) — athletes subject to drug testing should be aware that many peptides, including BPC-157 and TB-500, are prohibited in competition
Sold in a grey market — often labeled "for research purposes only," which is a regulatory workaround, not a safety assurance
When a compound is purchased outside of a regulated pharmacy, there is no guarantee that what is in the vial is what is on the label — in terms of identity, purity, or concentration. This is a genuine safety concern, not a theoretical one.
Why the Interest?
I understand the appeal. Recovery from orthopedic surgery or a significant injury is long, often frustrating, and there is a real desire to do everything possible to optimize outcomes. When conventional medicine says "rest and physical therapy," and someone online claims a peptide cut their recovery in half, it is not surprising that patients want to explore it.
I also understand that some patients report subjective benefit. That is real to them. But subjective improvement in the absence of controlled data is difficult to interpret — it may reflect placebo effect, natural healing, concurrent rehabilitation, or genuine biological activity. We cannot know which without rigorous study.
What I tell patients
My standard position is this:
The theoretical biological rationale for some peptides is scientifically plausible
The current human evidence does not support their use as a proven treatment
The regulatory environment means product quality cannot be assured
Athletes subject to drug testing should avoid them entirely
Anyone considering peptides should do so only after an informed conversation with their physician — not based on social media recommendations
I do not dismiss patients who ask about peptides. I take the question seriously, give them an honest answer, and focus our conversation on what the evidence does support: optimized nutrition, sleep, structured rehabilitation, and when appropriate, evidence-based biologics such as PRP.
What does have evidence?
If the goal is optimizing recovery from musculoskeletal injury or surgery, the interventions with the strongest evidence base are less exciting but more reliable:
Protein intake — adequate dietary protein (1.6–2.2g/kg/day) supports tissue repair and muscle recovery
Sleep — the most underrated recovery tool. Growth hormone is released primarily during deep sleep. Inadequate sleep impairs healing biology directly.
Structured rehabilitation — progressive loading drives tendon and ligament remodeling. There is no substitute.
Creatine monohydrate — one of the most studied supplements in sports medicine, with genuine evidence for muscle preservation during immobilization
Vitamin D and collagen with vitamin C — both have emerging evidence for supporting connective tissue health
PRP (platelet-rich plasma) — not universally effective across all conditions, but has supporting evidence in specific applications including tendinopathy
Peptides vs PRP — an important distinction
Patients sometimes ask whether peptides and PRP (platelet-rich plasma) are similar. They are both sometimes described as "biologics" or "regenerative medicine," but they are not comparable in terms of regulatory status, evidence quality, or clinical readiness.
PRP is derived from the patient's own blood, processed to concentrate growth factors, and administered in a supervised clinical setting. It has an established and growing clinical evidence base for specific applications — including tendinopathy and certain soft tissue injuries — and is used within a regulated medical framework.
Most peptides, by contrast, remain at preclinical or early investigational stages for orthopedic applications. The two are not interchangeable and should not be discussed as equivalent options.
What the latest literature says
A 2026 critical review by Coutinho and colleagues published in the Journal of Sports Medicine and Physical Fitness offers one of the most rigorous recent appraisals of commonly discussed peptides in athletic contexts. Their conclusions are consistent with the principles outlined in this article: the science is early, enthusiasm must be grounded in evidence, and significant gaps remain between preclinical findings and clinical application in humans.
That review is worth reading for patients who want to go deeper into the literature, but its bottom line is the same: we are not there yet in terms of proven human benefit.
Summary
Peptides are a genuinely interesting area of biology. The science may eventually catch up to the enthusiasm. But as of today, the evidence in humans is scarce, the regulatory environment is uncontrolled, and patients deserve to know that before making decisions about what they put in their bodies.
If you have questions about recovery optimization, for an upcoming surgery, a current injury, or long-term joint health, that is exactly the kind of conversation worth having in clinic, where we can look at your specific situation and focus on what is actually supported by evidence.
References
Coutinho et al. Peptides in sports medicine and athletic recovery: a critical review of the emerging evidence. Journal of Sports Medicine and Physical Fitness. 2026.
James C. Messina, MD
Orthopedic Surgery · Sports Medicine · NYU Langone Long Island
Commack, NY · 631-919-6262
